Avalo Therapeutics, Inc. 8-K

What Happened
Avalo Therapeutics, Inc. announced on January 12, 2026 (via a Current Report on Form 8-K and an updated investor presentation on its website) that it estimates it had approximately $98 million of cash, cash equivalents and short-term investments as of December 31, 2025. The company attached the investor presentation as Exhibit 99.1 to the 8-K and said the presentation will be used in investor meetings; it also stated it has no obligation to update the presentation materials.

Key Details

• Estimated cash, cash equivalents and short-term investments: approximately $98 million as of December 31, 2025.
• 8-K filing date: January 12, 2026; investor presentation posted to the company website and attached as Exhibit 99.1.
• Presentation will be used in investor meetings; company disclaims any obligation to update or amend the presentation.

Why It Matters
This 8-K gives investors a recent liquidity snapshot for Avalo as of year-end 2025, which is a key input when assessing the company’s runway and near-term financing needs. The investor presentation may also provide business or program updates that management will use in meetings with investors. The disclosure is factual and limited to the estimated year‑end cash balance and the availability of the presentation; it does not include audited financial statements or additional operating results.